Pages that link to "Q63370740"
Jump to navigation
Jump to search
The following pages link to Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1 (Q63370740):
Displaying 13 items.
- HIP1R targets PD-L1 to lysosomal degradation to alter T cell-mediated cytotoxicity (Q58611450) (← links)
- Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway (Q90171110) (← links)
- Metabolic interventions in the immune response to cancer (Q92023481) (← links)
- Blocking PD-L1 for anti-liver cancer immunity: USP22 represents a critical cotarget (Q92133055) (← links)
- AMP-activated protein kinase: the current landscape for drug development (Q92342120) (← links)
- Competitive glucose metabolism as a target to boost bladder cancer immunotherapy (Q92740760) (← links)
- Immune checkpoint signaling and cancer immunotherapy (Q95936576) (← links)
- Autophagy deficiency promotes triple-negative breast cancer resistance to T cell-mediated cytotoxicity by blocking tenascin-C degradation (Q98176922) (← links)
- The updated landscape of tumor microenvironment and drug repurposing (Q98725916) (← links)
- Metformin and cancer immunity (Q99637262) (← links)
- Targeted degradation of immune checkpoint proteins: emerging strategies for cancer immunotherapy (Q100465053) (← links)
- PD-L1 degradation pathway and immunotherapy for cancer (Q101409813) (← links)
- Cancer cell metabolic reprogramming: a keystone for the response to immunotherapy (Q101573919) (← links)